IRadimed Corp reports results for the quarter ended in September 30 - Earnings Summary

Reuters11-01

* IRadimed Corp reported quarterly adjusted earnings of 43 cents​​ per share for the quarter ended September 30, identical to the same quarter last year. The mean expectation of two analysts for the quarter was for earnings of 39 cents per share. Wall Street expected results to range from 38 cents to 39 cents per share.

* Revenue rose 11% to $18.33 million from a year ago; analysts expected $18.10 million.

* IRadimed Corp's reported EPS for the quarter was 40 cents​.

* The company reported quarterly net income of $5.05 million.

* IRadimed Corp shares had risen by 5.3% this quarter and gained 11.5% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts was unchanged in the last three months.​

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

Wall Street's median 12-month price target for IRadimed Corp is $60.00 This summary was machine generated from LSEG data November 1 at 03:46 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 0.39 0.43 Beat

Jun. 30 2024 0.37 0.42 Beat

Mar. 31 2024 0.34 0.36 Beat

Dec. 31 2023 0.40 0.39 Missed

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment